Monoamine, diamide, thiol-containing metal chelating agents

Details Monoamine, diamide, thiol-containing metal chelating agents Monoamine, diamide, thiol-containing metal chelating agents

2007-07-03

2007-07-03

Hartley, Michael G. (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001650, C558S254000

Reexamination Certificate

active

08253973

ABSTRACT:
Therapeutically active thiazole derivatives of formula (I) wherein R1-R2, X and X′ as are defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor • (TGF-•), and pharmaceutical compositions for use in suchtherapy.

REFERENCES:
patent: 4434151 (1984-02-01), Byrne et al.
patent: 4444690 (1984-04-01), Fritzberg
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4571430 (1986-02-01), Byrne et al.
patent: 4575556 (1986-03-01), Byrne et al.
patent: 4668503 (1987-05-01), Hnatowich
patent: 4732864 (1988-03-01), Tolman
patent: 4832940 (1989-05-01), Ege et al.
patent: 4861869 (1989-08-01), Nicolotti et al.
patent: 4925650 (1990-05-01), Nosco et al.
patent: 4943523 (1990-07-01), Stavrianopoulos
patent: 4965392 (1990-10-01), Fritzberg et al.
patent: 4986979 (1991-01-01), Morgan et al.
patent: 5061641 (1991-10-01), Schochat et al.
patent: 5091514 (1992-02-01), Fritzberg et al.
patent: 5095111 (1992-03-01), Lever et al.
patent: 5112953 (1992-05-01), Gustavson et al.
patent: 5175257 (1992-12-01), Kasina et al.
patent: 5180816 (1993-01-01), Dean et al.
patent: 5196515 (1993-03-01), Lever et al.
patent: 5248764 (1993-09-01), Flanagan et al.
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5662885 (1997-09-01), Pollak et al.
patent: 5688485 (1997-11-01), Harris
patent: 5780006 (1998-07-01), Pollak et al.
patent: 84109831.2 (1985-05-01), None
patent: 85104959.3 (1985-12-01), None
patent: 86105920.2 (1986-11-01), None
patent: 87300426.1 (1987-09-01), None
patent: 87118142.6 (1988-06-01), None
patent: 88102252.9 (1988-08-01), None
patent: 88104755.9 (1988-09-01), None
patent: 8802276 (1989-01-01), None
patent: 90306427.5 (1990-12-01), None
patent: 90402206.8 (1991-02-01), None
patent: WO9101144 (1991-02-01), None
patent: 483704 (1992-05-01), None
patent: 8927255.3 (1990-06-01), None
patent: WO8503231 (1985-08-01), None
patent: WO8807382 (1988-10-01), None
patent: WO8907456 (1989-08-01), None
patent: WO8909405 (1989-10-01), None
patent: 8901854 (1989-11-01), None
patent: WO8912625 (1989-12-01), None
patent: WO9006323 (1990-06-01), None
patent: WO9015818 (1990-12-01), None
patent: WO9109876 (1991-07-01), None
patent: 9103116 (1991-11-01), None
patent: 9204559 (1992-12-01), None
patent: WO9312819 (1993-07-01), None
patent: WO9315770 (1993-08-01), None
patent: WO9321151 (1993-10-01), None
Rhodes, 1974, “Considerations in the Radiolabeling of Albumin”,Sem. Nucl. Med. 4: 281-293.
Davidson et al., 1981, “A New Class of Oxotechnetium(5+) Chelate Complexes containing a TcON2S2Core”,Inorg. Chem. 20: 1629-1632.
Fritzberg et al., 1982, “Synthesis and Biological Evaluation of Tc-99m N,N'-Bis(mercaptoacetyl)-2,3-diaminopropanoate: A Potential Replacement for [131I]o-iodohippurate”,J. Nucl. Med. 23: 592-598.
Khaw et al., 1982, “Technetium-99m Labeling of Antibodies to Cardiac Myosin Fab and to Human Fibrinogen”,J. Nucl. Med. 23: 1011-1019.
Byrne and Tolman, 1983, “Technetium-99m Bifunctional Chelating Agent—Thiolactone for Coupling to Biomolecules, N2S2Ligand for Chelation to Technetium”,J. Nucl. Med. 24: P126.
Bryson et al., 1988, “Neutral Technetium(V) Complexes with Amide-Thiol-Thioether Chelating Ligands”, Inorg. Chem. 27: 2154-2161.
Misra et al., 1989, “Synthesis of a Novel Diaminodithiol Ligand for Labeling Proteins and Small Molecules with Technetium-99m”,Tet. Lett. 30: 1885-1888.
Baidoo et al., 1990, “Synthesis of a Diaminodithiol Bifunctional Chelating Agent for Incorporation of Technetium-99m into Biomolecules”,Bioconjugate Chem. 1: 132-137.
Taylor et al., 1990, “Brain Uptake and Retention of [Tc-99m]T691: A Potential New Tracer of Cerebral Blood Flow”,J. Nucl. Med. 32: 885 (Abst.).
Knight et al., 1990, “Thrombus Imaging with Tc-99m Synthetic peptides Reactive with Activated Platelets”, J. Nucl. Med. 31: 757 #209.
Schwartz et al., 1991, “Preparation of Hydrazino-Modified Proteins and Their Use for the Synthesis of99mTc-Protein Conjugates”.Bioconjugate Chem. 2: 333.
Bryson et al., 1990, “Protecting Groups inb the Preparation of Thiolate Complexes of Technetium”, Inorg. Chem. 29: 2948-2951.
Kwekkeboom et al., 1991, “[In-111-DTPA-D-Phe]1-Octreotide Scintigraphy in Neuro-endocrine Tumors”, J. Nucl. Med. 32: 981, Abstract #305.
Albert et al., 1991, “A Somatostatin Ananlogue to Image SS-Receptor-Positive Tumors: [111In-DTPA-DPhe]1-Octreotide (SDZ 215-811)”, Abstract LM10, 12th American Peptide Symposium.
Cox et al., 1991, “Technetium Labeled Somatostatin: A Potential Agent for In Vivo Tumor Localization”, Abstract, 7th International Symposium on Radiopharmacology, p. 16.
Babich et al., 1993, “Technetium-99m-Labeled Hydrazino Nicotinamide Derivatized Chemotactic Peptide Analogs for Imaging Focal Sites of Bacterial Infection”,J. Nucl. Med. 34: 1964-1974.

Affiliated with

Also associated with

Rating

Monoamine, diamide, thiol-containing metal chelating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoamine, diamide, thiol-containing metal chelating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoamine, diamide, thiol-containing metal chelating agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3778157